INBSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends June 30

INTELLIGENT BIO SOLUTIONS INC.

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K/A on Oct 21, 2026

$1.53+0.03 (+2.00%)

Close on Oct 19, 2026

Market cap: $3.83M
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Intelligent Bio Solutions reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Intelligent Bio Solutions's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Intelligent Bio Solutions's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Feb 12, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is INBS.

Revenue growth38.1% · median 17.6%

Gross margin48.6% · median 60.9%

Operating margin-299.1% · median -847.4%

Net margin-294.9% · median -735.8%

Company	Revenue	Growth
BTCY	$16.40M	+13.4%
LUCD	$5.45M	+24.9%
INBS	$4.22M	+38.1%
FEMY	$2.30M	+21.9%
CODX	$721.39K	-28.1%
ICCM	–	–

Company

Next earnings (est.): Nov 6, 2026, after close
Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: June 30
Employees: 14
Held by institutions: 6.0%
Auditor: UHY LLP
SEC CIK: 1725430

Advertisement
300 × 250